리소자임 항체 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Lysozyme Antibody Market

The future of the global lysozyme antibody market looks promising with opportunities in the immunohistochemistry and western blot markets. The global lysozyme antibody market is expected to reach an estimated $180 million by 2035 from $120 million in 2027 with a CAGR of 5.4% from 2027 to 2035. The major drivers for this market are the increasing demand for precise research antibodies, the rising use in diagnostic assay development, and the growing adoption in biomedical research studies.

• Lucintel forecasts that, within the type category, recombinant monoclonal lysozyme antibody is expected to witness the highest growth over the forecast period due to more reliance on recombinant monoclonal antibodies in diagnostics.
• Within the application category, immunohistochemistry is expected to witness the highest growth over the forecast period due to rising use of immunohistochemistry by diagnostic pathology labs.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to new and increasing diagnostic laboratory and research-related construction activities.

Emerging Trends in Lysozyme Antibody Market

Between 2025 and 2027, the market for lysozyme antibodies will expand from a research market to an application market to include immunoassays and other forms of infectious disease and bioprocess testing. According to Lucintel, biomedical customers prefer specificity and continuity of supply to other considerations when sourcing antibodies.

• Validation of Antibody Specificity: In 2025, suppliers released data to validate antibodies for use in ELISA, western blot, and IHC. Of the 148 amino acids that make up the structure of lysozyme, customers can choose specific epitope sequences. As customers prefer to use validated reagents in their assays, this data will facilitate antibody purchases.
• Multiplex and Digital Assays: Antibody panels for various forms of inflammation and infection will utilize multiplex assays to measure 10 or more markers. The assays will be perform higher throughput functions for research and bioprocessing.
• Recombinant Antibodies: To meet the criteria for greater consistency in antibodies, suppliers will move away from variable hybridoma antibodies. In 2025, several suppliers provided data to demonstrate the high level of consistency and reproducibility for antibody lots. This data will facilitate purchases of recombinant antibodies.
• Automation-ready Formats: There is increasing demand for antibodies packaged in smaller volumes, conjugated antibodies, and reagent kits compatible with 96- and 384-well plates. The market will benefit suppliers that provide appropriate documentation for instrument-controlled assays. Additionally, it will benefit suppliers that provide constancy in antibody concentrations.
• Regional Supply Resilience: Refinancing by greater use of local distributors will continue until 2027. Qualification of local distributors will require the simultaneous use of two local distributors. Price will not be the only factor in supplier selection. The dependability of a supplier to promptly fulfill a shipment will also play a role. Of particular interest will be lysozyme antibodies, which require refrigerated transport and storage.

The antibodies and formats with documented performance will continue to have the largest market share. The market will also benefit formats with validated performance for use in bioprocessing. Price will not be the only factor in supplier selection. The evidence supporting a supplier's antibodies, such as documentation of performance and studies on automation, will be the factor that gives a supplier a competitive edge.

Recent Developments in the Lysozyme Antibody Market

The lysozyme antibody market is picking up momentum through 2025-2027, driven by research labs pushing for better validation, multiplex immunohistochemistry capabilities, and antibodies that deliver consistent, reproducible results. Growth in this space remains fragmented, with specialist suppliers going head-to-head against large catalog vendors. According to Lucintel, life-science research spending and customized assay development are the primary forces supporting demand. While commercial change is happening gradually, application requirements are getting noticeably stricter.

• Validated Antibody Portfolios: Suppliers are shifting focus toward expanding recombinant and application-tested lysozyme antibodies, moving away from broad, lightly documented catalogs. Abcam reported more than 110,000 products in its 2024 annual reporting cycle, as of March 2025. Over the next three to five years, better validation is likely to shape purchasing decisions as laboratories work to cut down on failed experiments and increasingly favor antibodies backed by traceable performance data.
• Multiplex Pathology Adoption: Immunohistochemistry providers are refining antibody panels for macrophage and myeloid-cell characterization, an area where lysozyme continues to serve as a practical marker. Roche posted first-quarter 2025 diagnostics sales of approximately $3.6 billion, as reported in April 2025, signaling ongoing investment in tissue-analysis platforms. As multiplex workflows become more common, demand should grow for compatible, low-background lysozyme antibodies.
• Recombinant Production Shift: Manufacturers are transitioning select research antibodies to recombinant formats to reduce lot-to-lot variation and strengthen supply continuity. Thermo Fisher Scientific reported first-quarter 2025 revenue of $10.4 billion in April 2025, reflecting sustained investment across its antibody and laboratory-products portfolio. This shift is likely to put pressure on conventional polyclonal products, particularly around consistency and documentation standards.
• Custom Assay Partnerships: Contract research organizations are increasingly bundling antibody supply with assay design, validation, and tissue-panel services. Charles River Laboratories recorded first-quarter 2025 revenue of $1.01 billion, reported in May 2025-a clear indicator of just how much outsourced research demand exists. As integrated purchasing becomes more common, some lysozyme antibody spending will likely shift away from catalog sales and toward project-based contracts.
• Digital Quality Documentation: Vendors are investing more in online datasheets, lot records, and application images, recognizing that buyers increasingly compare antibodies remotely before purchasing. The FDA's 2025 budget request came in at roughly $6.9 billion, as of March 2025, supporting the broader regulatory and laboratory-quality infrastructure. Suppliers who can clearly demonstrate specificity, reproducibility, and suitability for regulated workflows will have an edge as documentation standards rise.

Rather than a dramatic surge, this market is set for steady, sustained expansion-closely tracking pathology research, immunology programs, and outsourced assay work. Suppliers offering recombinant formats, credible validation, and dependable documentation are best positioned to gain ground. Price competition will likely stay intense in routine research applications, but specialized tissue panels offer room for stronger margins. Ultimately, it's product quality-not just the size of a catalog-that will determine who succeeds commercially in this space.

Strategic Growth Opportunities in the Lysozyme Antibody Market

The market for antibodies based on lysozyme is expected to develop in the context of research focused on infectious diseases, as well as in the analysis of biologics and biomarkers. In the 2024-2026 period, better performance of immunoassays and the growing demand for standardization and reproducibility of reagents in the biomedical field will expand the possibilities for the use of lysozyme-based antibodies. According to Lucintel, opportunities lie in the development of a service-oriented model and in the supply of antibodies according to geographic needs.

• Clinical Biomarkers: Lysozyme has been studied in relation to several pathologies, including inflammatory and hematological conditions. In January 2025, the PubMed database reported more than 1000 biomedical publications related to lysozyme. In the following years, it is expected that the commercialization of adequate antibody panels will allow the inclusion of this biomarker in clinical tests.
• Bioprocess: It is expected that the industry will need antibodies to detect host-cell and other process-related impurities. The FDA's public database of Biologics License Applications listed more than 100 requests in March 2025. The increasing number of Biologics in the industry will create a greater demand for comparable tests.
• Spatial and Multiplexed Omics: In June 2025, 10x Genomics announced the launch of a product for spatial proteomics. The company focused on the development of antibodies for spatial and multiplexed omics for the analysis of tissue. Other companies will most likely follow this trend.
• Supply Expansion: Currently, suppliers can profitably expand their businesses by localizing their supplies and services in the Asia-Pacific, Latin America and the Middle East regions. The WHO report published in April 2025, indicated that 100+ countries had established surveillance on antimicrobial resistance. In the near future, increasing local research efforts in different regions are anticipated to stimulate localized demands for Lysozyme Antibody products and related services.
• Custom Antibody Services: : The demand for species-specific and application-tested antibodies is growing, particularly in academic and biotech markets. In February 2026, Thermo Fisher Scientific announced serving 160+ countries. As customers value customization over mass production, the Antibody Services market is also projected to favor specialized services.

Rising customer awareness for validated performance and traceability in supplies is expected. Localizing and integrating supply and service networks, coupled with local demand, will be key for market differentiation. The market will remain small, but stable and predictable, in the short term (2029).

Lysozyme Antibody Market Drivers and Challenges

While The Development of Biotechnology, Economy and Regulation Affect The Entire Market, Each Individual Segment May Have Specific Limitations. Example: With the advancement of recombinant DNA technology, antibody engineering and other biotechnologies, demands for detecting and recognizing biomarkers continue to increase. However, the high cost for development and commercialization, along with market competition and the variability of laboratory conditions, create challenges for the market. Lucintel believes that in the future, market competition will be primarily influenced by the pace of innovation, price and degree of acceptance within the pharmaceutical, academic and clinical fields.

The factors responsible for driving this market include:

• Research on Infectious Diseases: Increasing research on cancer and other infectious and inflammatory diseases continues to fuel demand for the investigation of lysozyme and other biomarkers.
• Antibody Engineering: Multiple technologies have improved the reproducibility, specificity, and throughput of antibody-based methods. In June 2025, the U.S. Food and Drug Administration (FDA) issued guidance on the analytical validation of biologics, creating a greater need for reference standards. It is expected that, in the next 3-5 years, improvements in lysozyme antibodies would result in a reduction of cross-reactive binding, increased lot-to-lot consistency, and extending the use of lysozyme antibodies in other areas such as multiplexed protein analysis.
• Diagnostic Development: Advances in immunology, digital pathology, and automation have increased the demand for antibodies and other reagents used for in-vitro diagnostics. In September 2025, several pathology laboratories adopted digital technologies for automation of diagnostic image analysis, increasing the need for antibodies and other reagents used in immunodiagnostics. It is expected that, in the next 3-5 years, the increasing use of artificial intelligence (AI) and automation in diagnostics would stimulate the development of antibodies for multi-marker and quantitative diagnostic tests.
• Biopharmaceutical Research: The implementation of personalized and precision medicine created an increased need for the development of diagnostics and therapeutics in immunology and other areas. It is expected that, in the next 3-5 years, significant increases in biologics development, together with the need for companion diagnostics, would increase the demand for validated lysozyme antibodies.
• Manufacturing Improvements: Ongoing efforts to optimize recombinant expression, purification, and quality control further enable consistency and reduce waste in biologics manufacturing. Efficiencies in digital management of the supply chain further enhance productivity. In April 2025, automation in antibody production was further improved to enable large-scale screening at the 384-well microplate format. It is expected that in the next 3 to 5 years, improvements in manufacturing will enhance the supply of antibodies and reduce the time required for their delivery, particularly for diablo-type antibodies.

The challenges facing this market include:

• Variability in Antibody Validation: Different methods for antibody fixation, epitope mapping, and sample preparation can result in variability in the results obtained by different laboratories. Reproducibility of biomedical research continued to gain emphasis in February 2025. It is expected that in the next 3 to 5 years, inconsistent performance of antibodies may stimulate supplier interest in lot-specific validation, and provision of usage and performance data.
• Jurisdictional Differences: Standards for antibodies used in research and diagnostics vary by country. In July 2025, sponsoring countries strengthened requirements for evidence regarding the analytical validity of diagnostic tests. In the next 3 to 5 years, it is expected that similar trends will increase the time and cost required for compliance. Suppliers wishing to market their products for clinical use will need to adapt their quality systems and documentation to comply with different country-specific requirements.
• Cost and Supply Constraints: Developing antibodies is complex and expensive. It requires various steps of testing and processing. Smaller laboratories do not have the means to support these processes. Additionally, smaller laboratories have limited budgets. In October 2025, the trends reported in the scientific community showed a continuing effort to reduce laboratory expenses. It is expected that in the next 3 to 5 years, requests for multipurpose antibodies will increase due to cost considerations. Raw material and cold-chain supply disruptions will result in delayed antibody deliveries and alert customers to look for other suppliers.

Rising investment in research and biopharmaceuticals is improving the antibody market by expanding the range of available applications. Providing reliable tools to detect biomarkers is important for diagnostic and prognostic purposes. However, high costs and regulatory issues create barriers to market entry. The antibody market is expected to grow in the next 5 years. Suppliers that can produce antibodies to a high standard and reliably meet customers' requirements will gain market share. Improving standardization and continuous funding for research will facilitate the positive growth trend of the market.

List of Lysozyme Antibody Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies lysozyme antibody market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lysozyme antibody market companies profiled in this report include-

• Zeta Corporation
• Invitrogen
• Novus Biologicals
• Bio SB
• Bio-Techne

Lysozyme Antibody Market by Segment

The study includes a forecast for the global lysozyme antibody market by type, application, and region.

Lysozyme Antibody Market by Type [Value ($M) from 2019 to 2035]:

• Monoclonal Lysozyme Antibody
• Polyclonal Lysozyme Antibody
• Recombinant Monoclonal Lysozyme Antibody

Lysozyme Antibody Market by Application [Value ($M) from 2019 to 2035]:

• Immunohistochemistry
• Western Blot
• Others

Lysozyme Antibody Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Lysozyme Antibody Market

Lysozyme antibodies are in higher demand for uses in immunoassays and research compared to antibodies used in therapeutics. In the next 2-3 years, the public funding environment and automation in biomedical research and diagnostics is expected to improve. Based on the latest report by Lucintel, continued and broadened focus by suppliers will be the main driver of growth in this market.

• United States: The U.S. Federal government and numerous biomedical suppliers focused in the U.S. further strengthened the market for antibodies. In December 2023, Danaher completed the acquisition of Abcam for $5.7 billion. The fiscal 2025 budget request by the NIH was for $51.1 billion. During the next 3-5 years, improvements in the U.S. biomedical research and diagnostics infrastructure and supply of research antibodies are expected to further strengthen the U.S. market for research and diagnostic antibodies.
• China: The continued development of the Chinese biotechnology industry and the focus of China's 14th Five-Year plan on biotechnology should further strengthen China's research reagent industry. Sino Biological plans to produce over 10,000 research reagents including antibodies and proteins. The continued focus of suppliers in China should also strengthen China's research reagent market.
• Germany: Germany has one of the more advanced antibody, reagent and diagnostics industries in Europe, and will host a significant fraction of the new antibody and reagent manufacturing capacity in the region. Merck recently announced a 1.5 billion Euro investment to build a research, development, and manufacturing facility for biopharmaceuticals in Darmstadt. By 2028, this facility will enable Merck to produce a wider range of antibodies and reagents, including lysozyme.
• India: Similar developments have occurred in India. The Department of Biotechnology received a significant increase in funding in the 2025-26 Union Budget to promote the development of biotechnology and biopharmaceuticals. In addition, the BioE3 policy aims to facilitate biomanufacturing and other research and innovation activities. Broader adoption of molecular diagnostic and research technologies will likely follow in the biomedical and allied research sectors.
• Japan: Japan has also focused on its reagent manufacturing capacity. The 2024 budget prioritized the manufacturing and import replacement of high-quality automated diagnostic systems and reagents. Fujirebio also announced plans to invest 10 billion yen to build a new manufacturing facility to produce a range of diagnostic reagents. Reliable reagents and antibodies will facilitate specialized research and diagnostic testing.

Features of the Global Lysozyme Antibody Market

• Market Size Estimates: lysozyme antibody market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: lysozyme antibody market size by type, application, and region in terms of value ($B).
• Regional Analysis: lysozyme antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the lysozyme antibody market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lysozyme antibody market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the lysozyme antibody market by type (monoclonal lysozyme antibody, polyclonal lysozyme antibody, and recombinant monoclonal lysozyme antibody), application (immunohistochemistry, western blot, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Lysozyme Antibody Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Monoclonal Lysozyme Antibody : Trends and Forecast 2019 to 2035
• 4.4 Polyclonal Lysozyme Antibody : Trends and Forecast 2019 to 2035
• 4.5 Recombinant Monoclonal Lysozyme Antibody : Trends and Forecast 2019 to 2035

5. Global Lysozyme Antibody Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Immunohistochemistry : Trends and Forecast 2019 to 2035
• 5.4 Western Blot : Trends and Forecast 2019 to 2035
• 5.5 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Lysozyme Antibody Market by Region

7. North American Lysozyme Antibody Market

• 7.1 Overview
• 7.2 North American Lysozyme Antibody Market by Type
• 7.3 North American Lysozyme Antibody Market by Application
• 7.4 The United States Lysozyme Antibody Market
• 7.5 Canadian Lysozyme Antibody Market
• 7.6 Mexican Lysozyme Antibody Market

8. European Lysozyme Antibody Market

• 8.1 Overview
• 8.2 European Lysozyme Antibody Market by Type
• 8.3 European Lysozyme Antibody Market by Application
• 8.4 German Lysozyme Antibody Market
• 8.5 French Lysozyme Antibody Market
• 8.6 Italian Lysozyme Antibody Market
• 8.7 Spanish Lysozyme Antibody Market
• 8.8 The United Kingdom Lysozyme Antibody Market

9. APAC Lysozyme Antibody Market

• 9.1 Overview
• 9.2 APAC Lysozyme Antibody Market by Type
• 9.3 APAC Lysozyme Antibody Market by Application
• 9.4 Chinese Lysozyme Antibody Market
• 9.5 Indian Lysozyme Antibody Market
• 9.6 Japanese Lysozyme Antibody Market
• 9.7 South Korean Lysozyme Antibody Market
• 9.8 Indonesian Lysozyme Antibody Market

10. ROW Lysozyme Antibody Market

• 10.1 Overview
• 10.2 ROW Lysozyme Antibody Market by Type
• 10.3 ROW Lysozyme Antibody Market by Application
• 10.4 Middle Eastern Lysozyme Antibody Market
• 10.5 South American Lysozyme Antibody Market
• 10.6 African Lysozyme Antibody Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Lysozyme Antibody Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Zeta Corporation
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Invitrogen
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Novus Biologicals
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Bio SB
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Bio-Techne
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Proteintech
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Bio-Rad Antibodies
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 NeoBiotechnologies
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Biopioneer
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Beyotime
  • Company Overview
  • Lysozyme Antibody Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us